Identification

Name
Coenzyme M
Accession Number
DB09110
Type
Small Molecule
Groups
Approved, Investigational
Description

Coenzyme M (commonly known by it's salt form, Mesna) is a synthetic sulfhydryl (thiol) compound and is used for prophylaxis of Ifosfamide and cyclophosphamide induced hemorrhagic cystitis. [2]

Structure
Thumb
Synonyms
  • 2-Mercaptoethane
  • 2-Mercaptoethanesulfonate
  • 2-mercaptoethanesulfonic acid
  • 2-mercaptoethanesulphonic acid
  • 2-mercaptoethylsulfonate
  • 2-sulfanylethylsulfonate
  • Coenzima M
  • Coenzym M
  • CoM
  • HS-CoM
  • reduced coenzyme M
  • reduced CoM
  • β-mercaptoethanesulfonic acid
Product Ingredients
IngredientUNIICASInChI Key
MesnaNR7O1405Q919767-45-4XOGTZOOQQBDUSI-UHFFFAOYSA-M
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MesnaInjection, solution100 mg/mLIntravenousBaxter Laboratories1988-12-30Not applicableUs
Mesna for InjectionSolution100 mgIntravenous; OralFresenius Kabi2002-08-22Not applicableCanada
MesnexTablet, film coated400 mg/1OralBaxter Laboratories2002-03-21Not applicableUs
MesnexInjection, solution100 mg/mLIntravenousBaxter Laboratories1988-12-30Not applicableUs
UromitexanSolution100 mgIntravenousBaxter Laboratories2012-04-13Not applicableCanada
UromitexanSolution100 mgIntravenous; OralBaxter Laboratories2001-03-06Not applicableCanada
Uromitexan Inj 100mg/mlLiquid100 mgIntravenous; OralBristol Labs Division Of Bristol Myers Squibb1989-12-312001-06-12Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MesnaInjection, solution100 mg/mLIntravenousMylan Institutional2012-04-032018-01-31Us
MesnaSolution100 mg/mLIntravenousGland Pharma Limited2017-12-20Not applicableUs
MesnaInjection, solution100 mg/mLIntravenousFresenius Kabi2001-09-05Not applicableUs
MesnaInjection, solution100 mg/mLIntravenousAlvogen, Inc.2018-03-29Not applicableUs
MesnaInjection, solution100 mg/mLIntravenousSagent Pharmaceuticals2010-12-01Not applicableUs
MesnaInjection, solution100 mg/mLIntravenousAGILA SPECIALTIES PRIVATE LIMITED2014-07-192017-09-28Us
MesnaInjection, solution100 mg/mLIntravenousAthenex Pharmaceutical Division, Llc.2018-02-28Not applicableUs
MesnaInjection, solution100 mg/mLIntravenousTeva Parenteral Medicines, Inc.2002-05-01Not applicableUs
International/Other Brands
Mistabron / Mistabronco
Categories
UNII
VHD28S0H7F
CAS number
3375-50-6
Weight
Average: 142.197
Monoisotopic: 141.975835438
Chemical Formula
C2H6O3S2
InChI Key
ZNEWHQLOPFWXOF-UHFFFAOYSA-N
InChI
InChI=1S/C2H6O3S2/c3-7(4,5)2-1-6/h6H,1-2H2,(H,3,4,5)
IUPAC Name
2-sulfanylethane-1-sulfonic acid
SMILES
OS(=O)(=O)CCS

Pharmacology

Indication

Mesna is a uroprotective agent and is used prophylactically to reduce ifosfamide and cyclophosphamide induced hemorrhagic cystitis. (2)

Structured Indications
Pharmacodynamics

Mesna binds to and inactivates acrolein there by preventing or reducing bladder problems

Mechanism of action

A metabolite called acrolein is produced when ifosfamide and cyclophosphamide are metabolized. (1) This metabolite concentrates in the bladder and causes cell death via upregulation of reactive oxygen species (ROS), and activates inducible nitric oxide synthase (iNOS) which leads to production of nitric oxide (NO). (1) Both ROS and NO produce products which are detrimental to lipids, proteins and DNA strands. (1) Furthermore, ROS stimulate gene expression of pro-inflammatory cytokines such as TNF-α AND IL-1β. (1) Acrolein may also lead to ulceration of the bladder urothelium. (1) Mesna protects against cyclophosphamide and ifosfamide induced hemorrhagic cystitis by binding to their toxic metabolites. (1) Mesna is metabolized to dimesna and excreted by the kidneys. (1) Glutathione dihydrogenase acts on the reabsorbed portion and produces free sulfhydryl groups. (1) These free sulfhydryl groups bind acrolein in the bladder, allowing effective excretion and prevention of toxic effects. (1) In addition, Mesna binds to and detoxifies a urotoxic ifosfamide metabolite called 4-hydroxy-ifosfamide.

Absorption

Peak plasma concentrations were reached within 1.5-4 hours for free mesna, and 3-7 hours for total mesna following oral administration. The average oral bioavailability is 58% for free mesna and 89% for total mesna. Food has no effect on the urinary availability of mesna.

Volume of distribution

Vd = 0.652 ± 0.242 L/Kg after intravenous administration of mesna.

Protein binding

Total plasma mesna is 28% protein bound. (3)

Metabolism

Mesna undergoes rapid oxidation to mesna disulfide (dimesna) which is its major metabolite.

Route of elimination

Within 24 hours, approximately 32% of administered dose is eliminated in the urine as mesna while 33% is eliminated as dimesna.

Half life

The elimination half-life is 0.36 hours for mesna and 1.17 hours for dimesna.

Clearance

Plasma clearance of mesna = 1.23 L/h/kg

Toxicity

The following adverse events were most common (>10%) when mesna was administered with ifosfamide: nausea, vomiting, fatigue, fever, abdominal pain, constipation, diarrhea, leukopenia, anorexia, thrombocytopenia, anemia, granulocytopenia, asthenia, headache, alopecia, and somnolence. Hypersensitivity reactions and dermatologic toxicity may occur in patients taking mesna; therefore, if either reaction occurs, mesna should be discontinued and patient should be provided with supportive care.

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
  1. Matz EL, Hsieh MH: Review of Advances in Uroprotective Agents for Cyclophosphamide and Ifosfamide-Induced Hemorrhagic Cystitis. Urology. 2016 Aug 23. pii: S0090-4295(16)30458-7. doi: 10.1016/j.urology.2016.07.030. [PubMed:27566144]
  2. Cutler MJ, Urquhart BL, Velenosi TJ, Meyer Zu Schwabedissen HE, Dresser GK, Leake BF, Tirona RG, Kim RB, Freeman DJ: In vitro and in vivo assessment of renal drug transporters in the disposition of mesna and dimesna. J Clin Pharmacol. 2012 Apr;52(4):530-42. doi: 10.1177/0091270011400414. Epub 2011 Apr 19. [PubMed:21505084]
  3. DynaMed [Link]
External Links
Human Metabolome Database
HMDB0003745
KEGG Compound
C03576
PubChem Compound
598
PubChem Substance
310265029
ChemSpider
578
ChEBI
17905
ChEMBL
CHEMBL1098319
HET
COM
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Coenzyme_M
ATC Codes
R05CB05 — MesnaV03AF01 — Mesna
AHFS Codes
  • 92:56.00 — Protective Agents
PDB Entries
1e6v / 1e6y / 1hbn / 1hbo / 1hbu / 1mro / 2c3c / 2c3d / 3m1v / 3m2r
show 25 more
FDA label
Download (3.61 MB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedTreatmentPrecursor Cell Lymphoblastic Leukemia-Lymphoma1
1Active Not RecruitingTreatmentMalignant Lymphomas1
1CompletedTreatmentCancers1
1CompletedTreatmentCancers / Leukemias1
1CompletedTreatmentLeukemia Acute Myeloid Leukemia (AML)1
1CompletedTreatmentLeukemias1
1CompletedTreatmentLymphoma, Hodgkins / Malignant Lymphomas1
1CompletedTreatmentNeuroblastomas1
1CompletedTreatmentSarcomas1
1CompletedTreatmentSclerosis, Progressive Systemic1
1Not Yet RecruitingTreatmentMalignant Neoplasms of Bone and Articular Cartilage / Malignant Neoplasms of Female Genital Organs / Malignant Neoplasms of Independent (Primary) Multiple Sites / Malignant Neoplasms of Lip Oral Cavity and Pharynx / Malignant Neoplasms of Male Genital Organs / Malignant Neoplasms of Mesothelial and Soft Tissue / Malignant Neoplasms of Thyroid and Other Endocrine Glands / Malignant Neoplasms of Urinary Tract / Melanoma and Other Malignant Neoplasms of Skin1
1RecruitingTreatmentAgnogenic Myeloid Metaplasia / Leukemias / Malignant Lymphomas / Smith-Magenis Syndrome1
1RecruitingTreatmentAplastic Anaemia (AA) / Chronic Leukemias / Congenital Hematological Disorder / Immune Deficiency Disorder / Leukaemia, Acute / Malignant Lymphomas / Metabolism Disorder / Multiple Myeloma (MM) / Myelodysplastic Syndromes / Tumors, Solid1
1RecruitingTreatmentMelanoma1
1RecruitingTreatmentSoft Tissue Sarcoma (STS)1
1TerminatedTreatmentBrain and Central Nervous System Tumors / Liver Cancer / Renal Cancers / Retinoblastoma / Sarcomas1
1TerminatedTreatmentLeukemias / Malignant Lymphomas / Plasma Cell Myeloma1
1TerminatedTreatmentLung Cancer Metastatic / Sarcoma, Osteogenic1
1TerminatedTreatmentNeoplasms, Kidney1
1, 2CompletedTreatmentAcute Lymphocytic Leukemia (ALL) / Leukemias1
1, 2CompletedTreatmentCancer, Breast1
1, 2CompletedTreatmentLymphoma, Hodgkins1
1, 2CompletedTreatmentMalignancies, Hematologic1
1, 2CompletedTreatmentMalignant Lymphomas1
1, 2CompletedTreatmentSarcomas1
1, 2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemias1
1, 2RecruitingTreatmentAcute Lymphocytic Leukemia (ALL) / B-lymphoid Malignancies / Chronic Lymphocytic Leukaemia (CLL) / Non-Hodgkin's Lymphoma (NHL)1
1, 2RecruitingTreatmentCrohn's Disease (CD)1
1, 2RecruitingTreatmentLeukemias / Myeloproliferative Disorders1
1, 2RecruitingTreatmentMelanoma1
1, 2TerminatedTreatmentGraft Versus Host Disease (GVHD) / Lupus Erythematosus1
1, 2TerminatedTreatmentMetastatic Cancers1
1, 2TerminatedTreatmentNeoplasm Metastases / Neoplasms, Breast1
1, 2Unknown StatusTreatmentCancer, Breast2
1, 2WithdrawnTreatmentLymphoma, Hodgkins / Malignant Lymphomas / Non-Hodgkin's Lymphoma (NHL)1
2Active Not RecruitingTreatmentAdvanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma / Non-Hodgkin's Lymphoma (NHL)1
2Active Not RecruitingTreatmentCancer, Breast1
2Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Lymphoma, Hodgkins / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Lymphoma, Low-Grade / Mantle Cell Lymphoma (MCL) / Small Lymphocytic Lymphoma (SLL) / T-Cell Lymphomas1
2Active Not RecruitingTreatmentFibrolamellar Hepatocellular Carcinoma / Hepatocellular Carcinoma (Fibrolamellar Variant) / Hepatocellular,Carcinoma1
2Active Not RecruitingTreatmentGerm Cell Tumors1
2Active Not RecruitingTreatmentLeukemias1
2Active Not RecruitingTreatmentLeukemias / Malignant Lymphomas / Transplantation, Stem Cell1
2Active Not RecruitingTreatmentLymphoma, Hodgkins1
2Active Not RecruitingTreatmentMalignant Lymphomas1
2Active Not RecruitingTreatmentNeoplasms, Brain / Tumors, Central Nervous System1
2CompletedPreventionChronic Renal Insufficiency / Contrast Media Exposition / Serum Creatinine Concentration1
2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemias1
2CompletedTreatmentAplastic Anaemia (AA)1
2CompletedTreatmentBlood Stem Cell Transplant Failure / Leukemias / Malignancies, Hematologic1
2CompletedTreatmentCancer, Breast1
2CompletedTreatmentCancer, Breast / Non-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentDisseminated Sclerosis1
2CompletedTreatmentEnd Stage Renal Disease (ESRD)1
2CompletedTreatmentEwing's Sarcoma (ES) / Neuroblastomas / Non-rhabdomyosarcoma Soft Tissue Sarcomas1
2CompletedTreatmentLeukemia, Lymphocytic, Acute / Leukemia, Myelocytic, Acute / Leukemia,Myeloid, Chronic / Non-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentLeukemias4
2CompletedTreatmentLeukemias / Malignant Lymphomas1
2CompletedTreatmentLupus Erythematosus, Systemic1
2CompletedTreatmentMalignant Lymphomas6
2CompletedTreatmentMalignant Lymphomas / Mantle Cell Lymphoma (MCL)1
2CompletedTreatmentNeuroblastomas1
2CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentRetinoblastoma1
2CompletedTreatmentSarcomas3
2Not Yet RecruitingTreatmentMalignant Neoplasms of Bone and Articular Cartilage / Malignant Neoplasms of Female Genital Organs1
2RecruitingSupportive CareSarcomas1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Chronic Myeloid Leukemia (CML) / Granulocytic Sarcoma / Juvenile Myelomonocytic Leukemia (JMML) / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndromes (MDS) / Non-Hodgkin's Lymphoma (NHL)1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemias1
2RecruitingTreatmentAcute Lymphocytic Leukemia (ALL) / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myeloid Leukemia (CML) / Leukemia Acute Myeloid Leukemia (AML) / Lymphoma, Hodgkins / Multiple Myeloma (MM) / Myelodysplastic Syndrome / Myeloproliferative Syndromes / Non-Hodgkin's Lymphoma (NHL) / Other Diseases of Blood and Blood-Forming Organs1
2RecruitingTreatmentBone Marrow Failure Syndromes / Severe Aplastic Anemia (SAA)1
2RecruitingTreatmentCancer of the Ovary / Childhood Germ Cell Tumor / Teratoma1
2RecruitingTreatmentEffects of Chemotherapy / Lung Cancer Non-Small Cell Cancer (NSCLC)1
2RecruitingTreatmentHematopoietic/Lymphoid Cancer1
2RecruitingTreatmentLeukemia, Lymphoblastic, Acute / Leukemias / Lymphoma, Lymphoblastic1
2RecruitingTreatmentLeukemias3
2RecruitingTreatmentLeukemias / Malignant Lymphomas1
2RecruitingTreatmentLeukemias / Malignant Lymphomas / Myeloproliferative Disorders / Plasma Cell Myeloma1
2RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2RecruitingTreatmentMalignant Lymphomas3
2RecruitingTreatmentMalignant Lymphomas / Mantle Cell Lymphoma (MCL)1
2RecruitingTreatmentMelanoma2
2RecruitingTreatmentNeuroblastomas1
2RecruitingTreatmentRetinoblastoma1
2RecruitingTreatmentSickle Cell Disorders1
2RecruitingTreatmentTesticular Cancer1
2TerminatedTreatmentAtypical Burkitt Lymphoma / Burkitt's Lymphoma / Non-Hodgkin's Lymphoma (NHL)1
2TerminatedTreatmentHaematological Malignancies1
2TerminatedTreatmentLeukemias / Pediatric Cancer1
2TerminatedTreatmentMedulloblastomas / Neoplasms, Brain / Primitive Neuroectodermal Tumor / Tumors, Central Nervous System1
2TerminatedTreatmentNeuroblastomas1
2TerminatedTreatmentSarcomas1
2TerminatedTreatmentTransplantation, Kidney1
2WithdrawnTreatmentB-cell Adult Acute Lymphoblastic Leukemia / Blastic Phase Chronic Myelogenous Leukemia / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia1
2WithdrawnTreatmentCrohn's Disease (CD)1
2, 3Active Not RecruitingTreatmentMultiple Myeloma (MM)1
3CompletedTreatmentCancer, Breast1
3CompletedTreatmentLeukemias1
3CompletedTreatmentLung Cancers1
3CompletedTreatmentLymphoma, Large-Cell, Diffuse1
3CompletedTreatmentMalignant Lymphomas1
3CompletedTreatmentNeoplasms, Brain / Tumors, Central Nervous System1
3CompletedTreatmentNeuroblastomas1
3CompletedTreatmentSarcomas1
3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 / BCR-ABL1 Fusion Protein Expression / Minimal Residual Disease / Philadelphia Chromosome Positive / T Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3RecruitingTreatmentRelapsing Remitting Multiple Sclerosis (RRMS)1
3TerminatedTreatmentLeukemias1
3Unknown StatusTreatmentLeukemias1
3Unknown StatusTreatmentSarcomas1
4Not Yet RecruitingTreatmentPleural Effusions1
Not AvailableCompletedSupportive CareNausea / Sarcomas / Vomiting1
Not AvailableCompletedTreatmentAdverse Effects of Medical Drugs / Effects of Chemotherapy / Prophylaxis of acute chemotherapy induced nausea and vomiting / Sarcomas1
Not AvailableCompletedTreatmentChildhood Germ Cell Tumor / Extragonadal Germ Cell Tumor1
Not AvailableRecruitingTreatmentAtypical Teratoid/Rhabdoid Tumor (AT/RT) / CNS Tumors / Ewing's Family Tumors / Germ Cell Tumors / Hepatoblastomas / Medulloblastomas / Primary Malignant Brain Neoplasms / Renal Tumors / Retinoblastoma / Rhabdomyosarcomas / Soft Tissue Sarcoma (STS) / Supra-tentorial Primative Neuro-Ectodermal Tumor (PNET)1
Not AvailableRecruitingTreatmentBare Lymphocyte Syndrome / CD40 Ligand Deficiency / Chediak-Higashi Syndrome / Chronic Granulomatous Disease (CGD) / Common Variable Immunodeficiency / Griscelli Syndrome / Hyper IgM Syndrome / Langerhan's Cell Histiocytosis / Lymphohistiocytosis, Hemophagocytic / Omenn's Syndrome / Reticular Dysgenesis / SCID / Wiskott-Aldrich Syndrome (WAS) / X-Linked Lymphoproliferative Disease1
Not AvailableRecruitingTreatmentHaemoglobinopathies congenital / Sickle Cell Disorders1
Not AvailableRecruitingTreatmentMalignancies, Hematologic1
Not AvailableRecruitingTreatmentMalignant Lymphomas1
Not AvailableRecruitingTreatmentMedulloblastomas1
Not AvailableSuspendedTreatmentDisseminated Neuroblastoma / Localized Resectable Neuroblastoma / Localized Unresectable Neuroblastoma / Regional Neuroblastoma / Stage 4S Neuroblastoma1
Not AvailableTerminatedTreatmentCancers / Leukemias / Lymphoma, Hodgkins / Malignant Lymphomas / Non-Hodgkin's Lymphoma (NHL)1
Not AvailableTerminatedTreatmentHemoglobin SC / Sickle Cell Disorders1
Not AvailableTerminatedTreatmentImplant Capsular Contracture1
Not AvailableTerminatedTreatmentLeukemias / Lymphoma, Hodgkins / Myeloproliferative Disorders / Non Hodgkin Lymphoma (NHL)1
Not AvailableTerminatedTreatmentSarcoma, Osteogenic1
Not AvailableTerminatedTreatmentThalassaemic disorders1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Injection, solutionIntravenous100 mg/mL
SolutionIntravenous100 mg/mL
Tablet, film coatedOral400 mg/1
SolutionIntravenous100 mg
SolutionIntravenous; Oral100 mg
LiquidIntravenous; Oral100 mg
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility12.7 mg/mLALOGPS
logP-1.5ALOGPS
logP-0.4ChemAxon
logS-1ALOGPS
pKa (Strongest Acidic)-1.2ChemAxon
pKa (Strongest Basic)-9.6ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area54.37 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity29.13 m3·mol-1ChemAxon
Polarizability12.54 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - GC-MS (2 TMS)GC-MSsplash10-00e9-7960000000-d0e9fc5f5629ba893d57
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - GC-MSGC-MSsplash10-00e9-7960000000-d0e9fc5f5629ba893d57
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-052u-2900000000-51cd7c5f2497db0c7a15
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-004m-7970000000-a5c3c33a78b251bdd12c
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-001i-9400000000-f69174f630c88b6e6c0b

Taxonomy

Description
This compound belongs to the class of organic compounds known as organosulfonic acids. These are compounds containing the sulfonic acid group, which has the general structure RS(=O)2OH (R is not a hydrogen atom).
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Organic sulfonic acids and derivatives
Sub Class
Organosulfonic acids and derivatives
Direct Parent
Organosulfonic acids
Alternative Parents
Sulfonyls / Alkanesulfonic acids / Alkylthiols / Organic oxides / Hydrocarbon derivatives
Substituents
Alkanesulfonic acid / Sulfonyl / Organosulfonic acid / Alkylthiol / Organic oxygen compound / Organic oxide / Hydrocarbon derivative / Organosulfur compound / Aliphatic acyclic compound
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
thiol, organosulfonic acid (CHEBI:17905)

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Substrate
General Function
Nadp binding
Specific Function
Maintains high levels of reduced glutathione in the cytosol.
Gene Name
GSR
Uniprot ID
P00390
Uniprot Name
Glutathione reductase, mitochondrial
Molecular Weight
56256.565 Da
References
  1. Ormstad K, Orrenius S, Lastbom T, Uehara N, Pohl J, Stekar J, Brock N: Pharmacokinetics and metabolism of sodium 2-mercaptoethanesulfonate in the rat. Cancer Res. 1983 Jan;43(1):333-8. [PubMed:6401168]

Drug created on September 17, 2015 15:16 / Updated on April 22, 2018 23:41